FLSM
STRO icon

Frazier Life Sciences Management’s Sutro Biopharma STRO Stock Holding History

Frazier Life Sciences Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-78,000
Closed -$2.71M – 57
2023
Q3 		$2.71M Hold
78,000
– – 0.18% 46
2023
Q2 		$3.63M Sell
78,000
-99,648
-56% -$4.96M 0.22% 44
2023
Q1 		$8.21M Hold
177,648
– – 0.59% 32
2022
Q4 		$14.4M Hold
177,648
– – 0.89% 22
2022
Q3 		$9.86M Hold
177,648
– – 0.76% 29
2022
Q2 		$9.26M Hold
177,648
– – 0.87% 30
2022
Q1 		$14.6M Buy
+177,648
New +$16.9M 1.24% 29

Other funds holding STRO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Frazier Life Sciences Management's STRO Position: Q4 2023 in Review

Frazier Life Sciences Management sold out of Sutro Biopharma (STRO) in Q4 2023, closing a stake of 78,000 shares — an estimated $2.71M sold.

Frazier Life Sciences Management first reported a position in STRO in Q1 2022 and held it in 7 quarters. The position peaked at $14.6M in Q1 2022. 114 funds tracked by Wall St. Rank hold STRO as of Q4 2023.

  • Frazier Life Sciences Management reported no remaining Sutro Biopharma position as of Q4 2023 after selling out during the quarter.
  • Frazier Life Sciences Management sold 78,000 Sutro Biopharma shares in Q4 2023, an estimated $2.71M.
  • Frazier Life Sciences Management first reported a position in Sutro Biopharma in Q1 2022 and held it in 7 quarters.
  • Frazier Life Sciences Management's Sutro Biopharma position peaked at $14.6M in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2023.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.